211 related articles for article (PubMed ID: 32619646)
21. Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review.
Lin M; Park S; Hayden A; Giustini D; Trinkaus M; Pudek M; Mattman A; Schneider M; Chen LYC
Ann Hematol; 2017 Aug; 96(8):1241-1251. PubMed ID: 28497365
[TBL] [Abstract][Full Text] [Related]
22. Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.
Paietta E; Nelson DL; Andersen J; Dutcher JP; Wiernik PH
Med Oncol; 1995 Jun; 12(2):121-4. PubMed ID: 8535662
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
24. Biological role of the soluble interleukin-2 receptor in sarcoidosis.
Vanmaris RMM; Rijkers GT
Sarcoidosis Vasc Diffuse Lung Dis; 2017; 34(2):122-129. PubMed ID: 32476833
[TBL] [Abstract][Full Text] [Related]
25. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
[TBL] [Abstract][Full Text] [Related]
26. Relationship of IL-2, IL-2R (CD25+), soluble IL-2R and IL-4 with disease activity in SLE patients.
Cuadrado MJ; Marubayashi M; Ortega C; Fernandez-Arcas N; Garcia-Cozar F; Pena J; Sanchez-Guijo P; Santamaria M
Lupus; 1993 Aug; 2(4):257-60. PubMed ID: 8268974
[TBL] [Abstract][Full Text] [Related]
27. A soluble 'anchorminus' interleukin 2 receptor suppresses in vitro interleukin 2-mediated immune responses.
Kondo N; Kondo S; Shimizu A; Honjo T; Hamuro J
Immunol Lett; 1988 Dec; 19(4):299-307. PubMed ID: 2977379
[TBL] [Abstract][Full Text] [Related]
28. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
[TBL] [Abstract][Full Text] [Related]
29. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
Elg SA; Hill RB; Heldman L; Ramakrishnan S
Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-2 and soluble interleukin-2 receptor in bronchoalveolar lavage fluid from patients with bronchial asthma.
Park CS; Lee SM; Chung SW; Uh S; Kim HT; Kim YH
Chest; 1994 Aug; 106(2):400-6. PubMed ID: 7774310
[TBL] [Abstract][Full Text] [Related]
31. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease.
Damle RN; Advani SH; Gangal SG
Int J Cancer; 1992 Jan; 50(2):192-6. PubMed ID: 1730512
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-2 signaling and the maintenance of self-tolerance.
Nelson BH
Curr Dir Autoimmun; 2002; 5():92-112. PubMed ID: 11826762
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of plasma IL-2 and sIL-2Rα in patients with first-ever ischaemic stroke.
Zhao H; Li F; Huang Y; Zhang S; Li L; Yang Z; Wang R; Tao Z; Han Z; Fan J; Zheng Y; Ma Q; Luo Y
J Neuroinflammation; 2020 Aug; 17(1):237. PubMed ID: 32795376
[TBL] [Abstract][Full Text] [Related]
34. The monocyte interleukin-2 receptor light chain: production of cell-associated and soluble interleukin-2 receptor by monocytes.
Kniep EM; Strelow I; Lohmann-Matthes ML
Immunology; 1992 Feb; 75(2):299-304. PubMed ID: 1551692
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis.
Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik JP; Cylwik B; Skowronski J; Chwiecko J
Clin Exp Rheumatol; 2003; 21(1):63-9. PubMed ID: 12673891
[TBL] [Abstract][Full Text] [Related]
36. [The performance of the automated immune chemiluminescent system "IMMULITE 2000XPi for the measurement of serum soluble IL-2 receptor in clinical samples].
Watanabe N; Nagatomo R; Okubo S; Yokota H; Masuda A; Ikeda H; Yatomi Y
Rinsho Byori; 2012 May; 60(5):422-8. PubMed ID: 22774570
[TBL] [Abstract][Full Text] [Related]
37. Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma.
Mizutani N; Goto-Koshino Y; Kurata K; Fujiwara-Igarashi A; Sakaguchi M; Asada M; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2020 Jul; 225():110054. PubMed ID: 32434088
[TBL] [Abstract][Full Text] [Related]
38. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue.
Kurane I; Innis BL; Nimmannitya S; Nisalak A; Meager A; Janus J; Ennis FA
J Clin Invest; 1991 Nov; 88(5):1473-80. PubMed ID: 1939640
[TBL] [Abstract][Full Text] [Related]
39. Release of sIL-2R alpha from and activation of native human peripheral blood mononuclear cells by recombinant IL-15.
Treiber-Held S; Stewart DM; Barraclough HA; Kurman CC; Nelson DL
Clin Immunol Immunopathol; 1996 Jul; 80(1):67-75. PubMed ID: 8674241
[TBL] [Abstract][Full Text] [Related]
40. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.
Srivastava MD; Srivastava A; Srivastava BI
Leuk Lymphoma; 1994 Jan; 12(3-4):241-51. PubMed ID: 7909467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
